Urtoxazumab is a humanized monoclonal antibody against diarrhoea caused by Escherichia coli, serotype O121. The drug is designed to bind to a toxin of this bacterium, so that it can be more easily broken down and eliminated from the body.[1][2]
References[edit]
- ^ International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organization.
- ^ López, EL; Contrini, MM; Glatstein, E; González Ayala, S; Santoro, R; Allende, D; Ezcurra, G; Teplitz, E; et al. (2009). "Safety and Pharmacokinetics of Urtoxazumab, a Humanized Monoclonal Antibody Against Shiga-Like Toxin 2 in Healthy Adults and Pediatric STEC- Infected Patients". Antimicrobial Agents and Chemotherapy. 54 (1): 239–243. PMC 2798559
. PMID 19822704. doi:10.1128/AAC.00343-09.
|
|
| Fungal ("-fung-") |
|
| Viral ("-v(i)[r]-") |
|
| Bacterial ("-ba(c)-") |
|
Human ("-bacu-")
|
|
|
Mouse ("-baco-")
|
|
|
|
|
|
Humanized ("-bazu-")
|
|
|
| Toxin ("-tox(a)-") |
|
Human ("-toxu-")
|
|
|
Chimeric ("-toxaxi-")
|
|
|
Humanized ("-toxazu-")
|
|
|
|
|
(what is this?) (verify)
